Sporadic Alzheimers disease accounts for more than 90 percent of all Alzheimers cases, yet it has remained among the least understood forms of the condition at the molecular level. Unlike familial Alzheimers, which is driven by dominant genetic mutations and often appears before age 65, the sporadic form arises from a complex mix of genetic and environmental risk factors that researchers are still working to untangle. A landmark study from Harvard Medical School has now created the first cell model of sporadic Alzheimers disease that consistently reproduces the same molecular abnormalities across multiple patient derived lines, removing a major obstacle for scientists seeking both causes and treatments.
At FOMAT, neurodegenerative disease research is an area of growing importance in our clinical trial portfolio. Alzheimers disease affects Hispanic and minority communities at disproportionately high rates, yet these populations remain underrepresented in the research that drives new treatments. Breakthroughs like this one are particularly significant because they open new doors for earlier intervention studies and more precise patient selection in future Alzheimers trials.
Building a Cell Model of Sporadic Alzheimers Disease
The research team, led by senior author Bruce Yankner, professor of genetics at the Blavatnik Institute at HMS, began by collecting skin cells from five people with sporadic Alzheimers disease and six healthy individuals of comparable ages. These adult cells were reprogrammed into induced pluripotent stem cells, which can develop into many other cell types. At first, the Alzheimers derived cells and the healthy controls appeared identical.
The differences emerged when the cells were guided to mature into neural progenitors, the stem cells that give rise to most brain cell types. DNA analyses revealed unusually high activity in genes related to neuron differentiation, neuron creation, and the formation of connections between neurons in the Alzheimers derived cells. The practical result was that these cells matured into neurons significantly faster than their healthy counterparts and became electrically excitable earlier and more vigorously as well.
The Role of REST in Sporadic Alzheimers Disease
To understand what was driving the accelerated differentiation, Yankner and colleagues focused on a protein called REST. REST is known to regulate neural differentiation during early development and has been shown to resurface in the aging brain, where it appears to offer protection against neurodegeneration and other age related stresses. In the sporadic Alzheimers disease cells, REST levels in the nucleus were lower than normal, and the REST that remained was not functioning correctly, failing to bind to genes as it should.
The researchers also found that the nuclei of the Alzheimers derived cells were more frequently misshapen and showed a higher rate of structural abnormalities in their membranes compared to healthy cells. These nuclear defects had been observed previously in the brains of people who died with Alzheimers, but their relationship to neurodegeneration had remained unclear.
Critically, these changes occurred independently of the two proteins most commonly associated with Alzheimers pathology. When amyloid beta production was shut off, the abnormalities persisted. When researchers looked for phosphorylated tau, the basis of neurofibrillary tangles, they found that the cellular changes had already occurred before any abnormal tau appeared.
Replicating the Sporadic Alzheimers Disease Model Across Labs
The findings were striking enough that the researchers initially questioned whether errors in stem cell reprogramming might explain them. To rule this out, the team partnered with collaborators at multiple institutions to replicate the results using sporadic Alzheimers disease induced pluripotent stem cells obtained from three independent laboratories. They also validated the findings in stem cells edited to carry the APOE4 gene variant, the most common genetic risk factor for Alzheimers, and in cerebral organoids, three dimensional brain like structures grown from induced pluripotent stem cells.
Genome wide profiling suggested that REST was the most likely gene regulator disrupted in APOE4 organoids, followed by two additional proteins that interact with REST. The consistency of the findings across multiple models and institutions significantly strengthens the case that these molecular changes are a genuine and reproducible feature of sporadic Alzheimers disease.
What This Means for Early Intervention and Drug Development
The implications of this cell model extend in two important directions. First, it suggests that the origins of a disease that typically manifests in older adults may actually be rooted in early neurodevelopment, decades before any symptoms appear. Second, the accelerated differentiation and REST dysregulation observed in the model may function as early biological markers of sporadic Alzheimers disease, creating an opportunity to detect predisposition and intervene before neurodegeneration becomes clinically apparent.
Yankner noted that while this model does not replicate the full aging process of an 80 year old brain, it does replay the developmental sequence using human derived cells in a way that earlier models based on familial Alzheimers could not. Study coauthor George Church emphasized the technology’s potential to uncover contributing factors to diseases that lack clear genetic drivers and take decades to manifest, allowing researchers to identify risk and test treatments far earlier than traditional approaches permit.
The study was published in Cell Reports and was supported by the National Institutes of Health, the Paul F. Glenn Foundation for Medical Research, and the Cure Alzheimers Fund, among other funders.
FOMAT conducts Alzheimers and neurodegenerative disease clinical trials at sites across the United States. To learn more or find an active study near you, visit FOMAT’s patient studies page.